ProPhase Labs (PRPH) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

PRPH Stock Forecast

ProPhase Labs stock forecast is as follows: an average price target of $14.00 (represents a 1678.00% upside from PRPH’s last price of $0.79) and a rating consensus of 'Hold', based on 1 wall street analysts offering a 1-year stock forecast.

PRPH Price Target

The average price target for ProPhase Labs (PRPH) is $14.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $14.00. This represents a potential 1678.00% upside from PRPH's last price of $0.79.

PRPH Analyst Ratings

Hold

According to 1 Wall Street analysts, ProPhase Labs's rating consensus is 'Hold'. The analyst rating breakdown for PRPH stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 1 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

ProPhase Labs Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
May 17, 2022	-	H.C. Wainwright	$14.00	$7.60	84.21%	1678.00%

Row per page

Go to

The latest ProPhase Labs stock forecast, released on May 17, 2022 by H.C. Wainwright company, set a price target of $14.00, which represents a 84.21% increase from the stock price at the time of the forecast ($7.60), and a 1678.00% increase from PRPH last price ($0.79).

ProPhase Labs Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$0.79	$0.79	$0.79
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of ProPhase Labs stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ProPhase Labs's last price of $0.79. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jul 21, 2022	Dawson James	-	Neutral	Downgrade

Row per page

Go to

ProPhase Labs's last stock rating was published by Dawson James on Jul 21, 2022. The company Downgrade its PRPH rating from "null" to "Neutral".

ProPhase Labs Financial Forecast

ProPhase Labs Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Jun 10	Mar 09	Mar 05	Jun 04	Mar 01	Mar 00	Dec 99	Mar 98	Jun 97
Revenue	-	-	-	-	-	-	-	-	$4.35M	$8.37M	-	$19.30M	$21.82M	$24.20M	$29.09M	$47.53M	$45.16M	$9.47M	$9.14M	$15.27M	$5.16M	$1.13M	$3.99M	-	-	-	-	-	-	-
Avg Forecast	$24.65M	$14.51M	$5.44M	$5.64M	$5.88M	$2.82M	$18.35M	$9.86M	$10.71M	$13.06M	$14.14M	$15.13M	$20.51M	$21.43M	$20.01M	$24.31M	$28.61M	$9.04M	$14.63M	$11.98M	$4.65M	$1.13M	$2.96M	$19.64M	$4.60M	$7.07M	$142.37K	$32.88M	$10.11M	$4.50M
High Forecast	$24.65M	$14.51M	$5.44M	$5.64M	$5.88M	$2.82M	$18.35M	$9.86M	$11.00M	$13.06M	$14.14M	$15.13M	$20.51M	$21.43M	$20.01M	$24.31M	$28.61M	$9.04M	$14.63M	$11.98M	$4.65M	$1.36M	$3.55M	$23.57M	$5.52M	$8.49M	$170.84K	$39.46M	$12.13M	$5.40M
Low Forecast	$24.65M	$14.51M	$5.44M	$5.64M	$5.88M	$2.82M	$18.35M	$9.86M	$10.40M	$13.06M	$14.14M	$15.13M	$20.51M	$21.43M	$20.01M	$24.31M	$28.61M	$9.04M	$14.63M	$11.98M	$4.65M	$904.00K	$2.37M	$15.72M	$3.68M	$5.66M	$113.89K	$26.31M	$8.09M	$3.60M
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	9	7	12	16	7	8	19	19	9
Surprise %	-	-	-	-	-	-	-	-	0.41%	0.64%	-	1.28%	1.06%	1.13%	1.45%	1.96%	1.58%	1.05%	0.62%	1.28%	1.11%	1.00%	1.35%	-	-	-	-	-	-	-

ProPhase Labs's average Quarter revenue forecast for Mar 24 based on 1 analysts is $9.86M, with a low forecast of $9.86M, and a high forecast of $9.86M. PRPH's average Quarter revenue forecast represents a 126.61% increase compared to the company's last Quarter revenue of $4.35M (Dec 23).

ProPhase Labs EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Jun 10	Mar 09	Mar 05	Jun 04	Mar 01	Mar 00	Dec 99	Mar 98	Jun 97
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	9	7	12	16	7	8	19	19	9
EBITDA	-	-	-	-	-	-	-	-	$-9.40M	$-6.48M	-	$2.16M	$-4.04M	$3.34M	$11.96M	$17.55M	$10.82M	$-2.97M	$-408.00K	$1.93M	$204.02K	$-2.17M	$-2.20M	-	-	-	-	-	-	-
Avg Forecast	$-1.64M	$-964.72K	$-361.69K	$-374.99K	$-390.94K	$-187.49K	$-1.22M	$2.43M	$-711.74K	$-868.32K	$-940.12K	$2.20M	$2.32M	$-1.93M	$-1.80M	$1.74M	$-2.58M	$-814.06K	$-1.32M	$1.38M	$-418.83K	$-2.17M	$-1.44M	$-209.67K	$-608.32K	$-593.38K	$-127.12M	$-3.42M	$2.91M	$2.02M
High Forecast	$-1.64M	$-964.72K	$-361.69K	$-374.99K	$-390.94K	$-187.49K	$-1.22M	$2.91M	$-691.14K	$-868.32K	$-940.12K	$2.65M	$2.79M	$-1.93M	$-1.80M	$2.09M	$-2.58M	$-814.06K	$-1.32M	$1.65M	$-418.83K	$-1.74M	$-1.15M	$-167.73K	$-486.65K	$-474.70K	$-101.70M	$-2.74M	$3.49M	$2.43M
Low Forecast	$-1.64M	$-964.72K	$-361.69K	$-374.99K	$-390.94K	$-187.49K	$-1.22M	$1.94M	$-731.68K	$-868.32K	$-940.12K	$1.76M	$1.86M	$-1.93M	$-1.80M	$1.39M	$-2.58M	$-814.06K	$-1.32M	$1.10M	$-418.83K	$-2.60M	$-1.72M	$-251.60K	$-729.98K	$-712.05K	$-152.54M	$-4.10M	$2.33M	$1.62M
Surprise %	-	-	-	-	-	-	-	-	13.21%	7.46%	-	0.98%	-1.74%	-1.73%	-6.64%	10.07%	-4.20%	3.65%	0.31%	1.40%	-0.49%	1.00%	1.53%	-	-	-	-	-	-	-

1 analysts predict PRPH's average Quarter EBITDA for Jun 23 to be $-940.12K, with a high of $-940.12K and a low of $-940.12K. This is -143.61% lower than ProPhase Labs's previous annual EBITDA (Mar 23) of $2.16M.

ProPhase Labs Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Jun 10	Mar 09	Mar 05	Jun 04	Mar 01	Mar 00	Dec 99	Mar 98	Jun 97
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	9	7	12	16	7	8	19	19	9
Net Income	-	-	-	-	-	-	-	-	$-8.75M	$-5.14M	-	$550.00K	$-2.44M	$968.00K	$7.45M	$12.49M	$6.53M	$-3.98M	$-1.34M	$1.06M	$-978.00K	$-2.23M	$-2.19M	-	-	-	-	-	-	-
Avg Forecast	$-2.29M	$-3.24M	$-4.96M	$-4.77M	$-4.58M	$-5.91M	$-1.53M	$1.33M	$-4.96M	$-3.72M	$-2.67M	$1.21M	$2.32M	$3.59M	$3.34M	$955.07K	$8.31M	$-1.61M	$3.59M	$755.00K	$-377.76K	$-2.25M	$-1.44M	$-258.23K	$-608.32K	$-593.38K	$-127.12M	$-3.42M	$1.80M	$1.24M
High Forecast	$-2.29M	$-3.24M	$-4.96M	$-4.77M	$-4.58M	$-5.91M	$-1.53M	$1.59M	$-4.77M	$-3.72M	$-2.67M	$1.45M	$2.79M	$3.59M	$3.34M	$1.15M	$8.31M	$-1.61M	$3.59M	$906.00K	$-377.76K	$-1.80M	$-1.15M	$-206.58K	$-486.65K	$-474.70K	$-101.70M	$-2.74M	$2.16M	$1.49M
Low Forecast	$-2.29M	$-3.24M	$-4.96M	$-4.77M	$-4.58M	$-5.91M	$-1.53M	$1.06M	$-5.15M	$-3.72M	$-2.67M	$966.53K	$1.86M	$3.59M	$3.34M	$764.06K	$8.31M	$-1.61M	$3.59M	$604.00K	$-377.76K	$-2.70M	$-1.72M	$-309.87K	$-729.98K	$-712.05K	$-152.54M	$-4.10M	$1.44M	$990.00K
Surprise %	-	-	-	-	-	-	-	-	1.76%	1.38%	-	0.46%	-1.05%	0.27%	2.23%	13.08%	0.79%	2.48%	-0.37%	1.40%	2.59%	0.99%	1.52%	-	-	-	-	-	-	-

ProPhase Labs's average Quarter net income forecast for Jun 23 is $-2.67M, with a range of $-2.67M to $-2.67M. PRPH's average Quarter net income forecast represents a -585.65% decrease compared to the company's last Quarter net income of $550.00K (Mar 23).

ProPhase Labs SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Jun 10	Mar 09	Mar 05	Jun 04	Mar 01	Mar 00	Dec 99	Mar 98	Jun 97
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	9	7	12	16	7	8	19	19	9
SG&A	-	-	-	-	-	-	-	-	$8.02M	-	-	$9.50M	$15.89M	$9.91M	$8.11M	$12.50M	$1.66M	$7.42M	$5.82M	$7.59M	$4.08M	$2.60M	$4.31M	-	-	-	-	-	-	-
Avg Forecast	$12.56M	$7.39M	$2.77M	$2.87M	$3.00M	$1.44M	$9.35M	$9.54M	$5.45M	$6.65M	$7.20M	$8.68M	$7.63M	$11.10M	$10.37M	$6.86M	$14.83M	$4.68M	$7.58M	$5.42M	$2.41M	$585.63K	$2.82M	$8.07M	$1.91M	$4.90M	$73.78K	$27.36M	$4.71M	$1.35M
High Forecast	$12.56M	$7.39M	$2.77M	$2.87M	$3.00M	$1.44M	$9.35M	$11.45M	$5.61M	$6.65M	$7.20M	$10.41M	$9.16M	$11.10M	$10.37M	$8.23M	$14.83M	$4.68M	$7.58M	$6.51M	$2.41M	$702.75K	$3.38M	$9.69M	$2.29M	$5.88M	$88.54K	$32.83M	$5.65M	$1.62M
Low Forecast	$12.56M	$7.39M	$2.77M	$2.87M	$3.00M	$1.44M	$9.35M	$7.64M	$5.30M	$6.65M	$7.20M	$6.94M	$6.11M	$11.10M	$10.37M	$5.49M	$14.83M	$4.68M	$7.58M	$4.34M	$2.41M	$468.50K	$2.25M	$6.46M	$1.53M	$3.92M	$59.02K	$21.89M	$3.77M	$1.08M
Surprise %	-	-	-	-	-	-	-	-	1.47%	-	-	1.10%	2.08%	0.89%	0.78%	1.82%	0.11%	1.58%	0.77%	1.40%	1.69%	4.44%	1.53%	-	-	-	-	-	-	-

ProPhase Labs's average Quarter SG&A projection for Mar 24 is $9.54M, based on 1 Wall Street analysts, with a range of $7.64M to $11.45M. The forecast indicates a 18.98% rise compared to PRPH last annual SG&A of $8.02M (Dec 23).

ProPhase Labs EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Jun 10	Mar 09	Mar 05	Jun 04	Mar 01	Mar 00	Dec 99	Mar 98	Jun 97
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	9	7	12	16	7	8	19	19	9
EPS	-	-	-	-	-	-	-	-	$-0.48	$-0.30	-	$0.03	$-0.15	$0.06	$0.48	$0.81	$0.42	$-0.24	$-0.09	$0.07	$0.23	$-0.15	$-0.17	-	-	-	-	-	-	-
Avg Forecast	$-0.12	$-0.17	$-0.26	$-0.25	$-0.24	$-0.31	$-0.08	$-0.28	$-0.26	$-0.20	$-0.14	$-0.10	$0.03	$0.19	$0.18	$0.39	$0.44	$-0.09	$0.19	$0.20	$-0.02	$-0.15	$-0.07	$-0.12	$-0.02	$-0.16	$-0.32	$0.34	$0.18	$0.09
High Forecast	$-0.12	$-0.17	$-0.26	$-0.25	$-0.24	$-0.31	$-0.08	$-0.28	$-0.25	$-0.20	$-0.14	$-0.10	$0.03	$0.19	$0.18	$0.39	$0.44	$-0.09	$0.19	$0.20	$-0.02	$-0.12	$-0.05	$-0.09	$-0.02	$-0.13	$-0.26	$0.41	$0.22	$0.11
Low Forecast	$-0.12	$-0.17	$-0.26	$-0.25	$-0.24	$-0.31	$-0.08	$-0.28	$-0.27	$-0.20	$-0.14	$-0.10	$0.03	$0.19	$0.18	$0.39	$0.44	$-0.09	$0.19	$0.20	$-0.02	$-0.18	$-0.08	$-0.14	$-0.02	$-0.19	$-0.39	$0.27	$0.14	$0.07
Surprise %	-	-	-	-	-	-	-	-	1.85%	1.54%	-	-0.30%	-6.00%	0.32%	2.72%	2.10%	0.95%	2.82%	-0.47%	0.34%	-11.50%	1.00%	2.43%	-	-	-	-	-	-	-

According to 1 Wall Street analysts, ProPhase Labs's projected average Quarter EPS for Jun 23 is $-0.14, with a low estimate of $-0.14 and a high estimate of $-0.14. This represents a -566.67% decrease compared to PRPH previous annual EPS of $0.03 (Mar 23).

ProPhase Labs Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
LMDX	LumiraDx	$0.02	$1.50	7400.00%	Buy
PRPH	ProPhase Labs	$0.79	$14.00	1672.15%	Hold
DRIO	DarioHealth	$0.80	$10.75	1243.75%	Buy
STIM	Neuronetics	$0.78	$8.00	925.64%	Buy
STRR	Star Equity	$3.09	$8.00	158.90%	Buy
GTH	Genetron	$4.03	$10.00	148.14%	-
BDSX	Biodesix	$1.26	$3.00	138.10%	Buy
XGN	Exagen	$3.00	$5.00	66.67%	Buy
SHC	Sotera Health Company	$13.88	$17.43	25.58%	Buy
OLK	Olink AB (publ)	$26.08	$21.50	-17.56%	Hold

PRPH Forecast FAQ

Is ProPhase Labs a good buy?

No, according to 1 Wall Street analysts, ProPhase Labs (PRPH) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of PRPH's total ratings.

What is PRPH's price target?

ProPhase Labs (PRPH) average price target is $14 with a range of $14 to $14, implying a 1678.00% from its last price of $0.787. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will ProPhase Labs stock go up soon?

According to Wall Street analysts' prediction for PRPH stock, the company can go up by 1678.00% (from the last price of $0.787 to the average price target of $14), up by 1678.00% based on the highest stock price target, and up by 1678.00% based on the lowest stock price target.

Can ProPhase Labs stock reach $1?

PRPH's average twelve months analyst stock price target of $14 supports the claim that ProPhase Labs can reach $1 in the near future.

What are ProPhase Labs's analysts' financial forecasts?

ProPhase Labs's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $36.91M (high $36.91M, low $36.91M), average EBITDA is $626.9K (high $1.11M, low $141.82K), average net income is $-10.691M (high $-10.425M, low $-10.957M), average SG&A $23.33M (high $25.24M, low $21.42M), and average EPS is $-0.91 (high $-0.91, low $-0.91). PRPH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $50.24M (high $50.24M, low $50.24M), average EBITDA is $-3.34M (high $-3.34M, low $-3.34M), average net income is $-15.263M (high $-15.263M, low $-15.263M), average SG&A $25.6M (high $25.6M, low $25.6M), and average EPS is $-0.8 (high $-0.8, low $-0.8).

Did the PRPH's actual financial results beat the analysts' financial forecasts?

Based on ProPhase Labs's last annual report (Dec 2022), the company's revenue was $122.65M, beating the average analysts forecast of $86.26M by 42.18%. Apple's EBITDA was $28.81M, beating the average prediction of $335.23K by 8493.85%. The company's net income was $18.46M, beating the average estimation of $10.21M by 80.92%. Apple's SG&A was $46.41M, beating the average forecast of $35.97M by 29.03%. Lastly, the company's EPS was $1.17, beating the average prediction of $0.777 by 50.64%. In terms of the last quarterly report (Dec 2023), ProPhase Labs's revenue was $4.35M, missing the average analysts' forecast of $10.7M by -59.36%. The company's EBITDA was $-9.402M, beating the average prediction of $-712K by 1220.99%. ProPhase Labs's net income was $-8.751M, beating the average estimation of $-4.961M by 76.41%. The company's SG&A was $8.02M, beating the average forecast of $5.45M by 47.07%. Lastly, the company's EPS was $-0.48, beating the average prediction of $-0.26 by 84.62%